Ferritin level predicts in-hospital mortality in hypertensive patients with COVID-19

Authors

DOI:

https://doi.org/10.14739/2310-1210.2023.1.266424

Keywords:

COVID-19, ferritin, hypertension, predictor, mortality

Abstract

Aim. This study aimed to establish the predictive ability of serum ferritin levels for severe / critical condition development, need for supplemental oxygen, and in-hospital mortality in hypertensive patients with COVID-19-associated pneumonia.

Materials and methods. 135 unvaccinated patients hospitalized for COVID-19-associated pneumonia were enrolled in the study. 78.5 % of patients were hypertensive.

Results. Among hypertensive patients, the median ferritin level at admission was 315.5 (169.0–396.0) ng/mL in patients with moderate condition, 374.0 (171.0–709.5) ng/mL in patients developed severe condition, and 489.0 (362.0–1128.5) ng/mL in patients developed critical condition (P = 0.03). Serum ferritin level at admission was higher in non-survivors (539.0 (440.0–1128.5) ng/mL) than that in survivors (332.5 (172.0–545.0) ng/mL, P = 0.02). Hypertensive patients who required supplemental oxygen had higher median serum ferritin level (446.0 (187.0–763.0) ng/mL) than patients without the requirement of supplemental oxygen (324.0 (165.0–401.0) ng/mL, P = 0.02). There was poor discrimination ability of ferritin level in the prediction of severe / critical conditions (AUC = 0.628, P = 0.02) and the need for supplemental oxygen (AUC = 0.629, P = 0.02). There was an acceptable discrimination ability of ferritin level in the in-hospital mortality prediction (AUC = 0.701, P = 0.03); the Youden index was 0.54, the associated criterion was >438.0 ng/mL with 83.3 % sensitivity and 70.7 % specificity. Ferritin level >438.0 ng/mL at admission was associated with a significant increase in in-hospital mortality (OR = 12.04 (2.47–58.62), P = 0.002).

Conclusions. Serum ferritin level at hospital admission increases with the severity of COVID-19 in hypertensive patients. Serum ferritin level predicts in-hospital mortality in hypertensive patients. However, its predictive ability for the disease progression to severe/critical conditions and the need for supplemental oxygen is poor. A ferritin level of 438.0 ng/mL is proposed to be a cut-off value for the prediction of in-hospital mortality.

Author Biographies

O. Z. Skakun, Ivano-Frankivsk National Medical University, Ukraine

MD, Postgraduate Student, Department of Internal Medicine No. 2 and Nursing

N. M. Seredyuk, Ivano-Frankivsk National Medical University, Ukraine

MD, PhD, DSc, Professor, Head of Department of Internal Medicine No. 2 and Nursing

References

World Health Organization. (2022). WHO COVID-19 dashboard. Website: https://covid19.who.int/

Hu, Y., Sun, J., Dai, Z., Deng, H., Li, X., Huang, Q., Wu, Y., Sun, L., & Xu, Y. (2020). Prevalence and severity of corona virus disease 2019 (COVID-19): A systematic review and meta-analysis. Journal of Clinical Virology, 104371. https://doi.org/10.1016/j.jcv.2020.104371

Pranata, R., Lim, M. A., Huang, I., Raharjo, S. B., & Lukito, A. A. (2020). Hypertension is associated with increased mortality and severity of disease in COVID-19 pneumonia: A systematic review, meta-analysis and meta-regression. Journal of the renin-angiotensin-aldosterone system : JRAAS, 21(2), 1470320320926899. https://doi.org/10.1177/1470320320926899

Huang, I., Pranata, R., Lim, M. A., Oehadian, A., & Alisjahbana, B. (2020). C-reactive protein, procalcitonin, D-dimer, and ferritin in severe coronavirus disease-2019: a meta-analysis. Therapeutic advances in respiratory disease, 14, 1753466620937175. https://doi.org/10.1177/1753466620937175

Dhar, S. K., Vishnupriyan, V., Damodar, S., Gujar, S., & Das, M. (2021). IL-6 and IL-10 as predictors of disease severity in COVID-19 patients: results from meta-analysis and regression. Heliyon, 7(2). e06155. https://doi.org/10.1016/j.heliyon.2021.e06155

Ma, A., Zhang, L., Ye, X., Chen, J., Yu, J., Zhuang, L., Weng, C., Petersen, F., Wang, Z., & Yu, X. (2021). High Levels of Circulating IL-8 and Soluble IL-2R Are Associated With Prolonged Illness in Patients With Severe COVID-19. Frontiers in immunology, 12, 626235. https://doi.org/10.3389/fimmu.2021.626235

Mehta, P., McAuley, D. F., Brown, M., Sanchez, E., Tattersall, R. S., Manson, J. J., & HLH Across Speciality Collaboration, UK (2020). COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet, 395(10229), 1033 1034. https://doi.org/10.1016/S0140-6736(20)30628-0

Kaushal, K., Kaur, H., Sarma, P., Bhattacharyya, A., Sharma, D. J., Prajapat, M., Pathak, M., Kothari, A., Kumar, S., Rana, S., Kaur, M., Prakash, A., Mirza, A. A., Panda, P. K., Vivekanandan, S., Omar, B. J., Medhi, B., & Naithani, M. (2022). Serum ferritin as a predictive biomarker in COVID-19. A systematic review, meta-analysis and meta-regression analysis. Journal of critical care, 67, 172-181. https://doi.org/10.1016/j.jcrc.2021.09.023

Cheng, L., Li, H., Li, L., Liu, C., Yan, S., Chen, H., & Li, Y. (2020). Ferritin in the coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis. Journal of clinical laboratory analysis, 34(10), e23618. https://doi.org/10.1002/jcla.23618

Kaur, D., Singh, H., Kaur, M., Bedi, G. K., & Sibia, R. P. S. (2020). Evaluation of serum ferritin levels in patients of hypertension. International Journal of Clinical Biochemistry and Research, 7(3), 317-319. https://doi.org/10.18231/j.ijcbr.2020.068

He, A., Yang, X., Ding, Y., Sun, L., Shi, M., & Li, R. (2022). The association between serum ferritin and blood pressure in adult women: a large cross-sectional study. Clinical and experimental hypertension, 44(6), 523-529. https://doi.org/10.1080/10641963.2022.2079667

Ministry of Health of Ukraine. (2022, February 22). Protokol "Nadannia medychnoi dopomohy dlia likuvannia koronavirusnoi khvoroby (COVID-19)" [Protocol "Providing medical aid for the treatment of coronavirus disease (COVID-19)" (No. 358)]. https://www.dec.gov.ua/wp-content/uploads/2022/02/2020_762_protokol_covid19.pdf

Shakaroun, D. A., Lazar, M. H., Horowitz, J. C., & Jennings, J. H. (2023). Serum Ferritin as a Predictor of Outcomes in Hospitalized Patients with Covid-19 Pneumonia. Journal of intensive care medicine, 38(1), 21-26. https://doi.org/10.1177/08850666221113252

Carubbi, F., Salvati, L., Alunno, A., Maggi, F., Borghi, E., Mariani, R., Mai, F., Paoloni, M., Ferri, C., Desideri, G., Cicogna, S., & Grassi, D. (2021). Ferritin is associated with the severity of lung involvement but not with worse prognosis in patients with COVID-19: data from two Italian COVID-19 units. Scientific reports, 11(1), 4863. https://doi.org/10.1038/s41598-021-83831-8

Ji, D., Zhang, D., Chen, Z., Xu, Z., Zhao, P., Zhang, M., Zhang L., Cheng G., Wang Y., Yang G., Liu H., Li B., Ji J., Lau G., & Qin E. (2020). Clinical Characteristics Predicting Progression of COVID-19 (2/17/2020). SSRN Electronic Journal. https://doi.org/10.2139/ssrn.3539674

Ahmed, S., Ansar Ahmed, Z., Siddiqui, I., Haroon Rashid, N., Mansoor, M., & Jafri, L. (2021). Evaluation of serum ferritin for prediction of severity and mortality in COVID-19- A cross sectional study. Annals of medicine and surgery (2012), 63, 102163. https://doi.org/10.1016/j.amsu.2021.02.009

Chen, J., He, Z. X., & Wang, F. K. (2022). Evaluation of ferritin level in COVID-19 patients and its inflammatory response. Applied nanoscience, 1-7. Advance online publication. https://doi.org/10.1007/s13204-021-02115-9

Gandini, O., Criniti, A., Gagliardi, M. C., Ballesio, L., Giglio, S., Balena, A., Caputi, A., Angeloni, A., & Lubrano, C. (2021). Sex-disaggregated data confirm serum ferritin as an independent predictor of disease severity both in male and female COVID-19 patients. The Journal of infection, 82(3), 414-451. https://doi.org/10.1016/j.jinf.2020.10.012

Downloads

Published

2023-03-06

How to Cite

1.
Skakun OZ, Seredyuk NM. Ferritin level predicts in-hospital mortality in hypertensive patients with COVID-19. Zaporozhye Medical Journal [Internet]. 2023Mar.6 [cited 2024Nov.24];25(1):11-5. Available from: http://zmj.zsmu.edu.ua/article/view/266424

Issue

Vol. 25 No. 1 (2023): Zaporozhye medical journal

Section

Original research

License

Authors who publish with this journal agree to the following terms:

    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.  Лицензия Creative Commons
    2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
    3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access)